rat anti mouse cd34 antibody  (Hycult Biotech)


Bioz Verified Symbol Hycult Biotech is a verified supplier
Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech rat anti mouse cd34 antibody
    Rat Anti Mouse Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34 antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 antibody - by Bioz Stars, 2024-04
    93/100 stars

    Images

    rat anti mouse cd34 antibody  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech rat anti mouse cd34 antibody
    Rat Anti Mouse Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34 antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 antibody - by Bioz Stars, 2024-04
    93/100 stars

    Images

    rat anti mouse cd34 antibody  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech rat anti mouse cd34 antibody
    Rat Anti Mouse Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34 antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 antibody - by Bioz Stars, 2024-04
    93/100 stars

    Images

    rat anti mouse cd34 antibody  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech rat anti mouse cd34 antibody
    ( a ) Correlation (ρ = 0.87, p < 10 −4 ) between AUC and <t>CD34</t> expression relative to total surface area in IHC and ( b ) Correlation (ρ = 0.72, p < 10 −4 ) between bound MBs signal intensity measured on late-phase BR55 ultrasound and area of VEGFR-2 expression in IHC, relative to tumor surface area. The outer edges of the shaded area represent the confidence bands, indicating the 95% confidence intervals for the mean of the Y-variable at each value of the X-variable. The p -value is indicated with “*” for significant values.
    Rat Anti Mouse Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34 antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 antibody - by Bioz Stars, 2024-04
    93/100 stars

    Images

    1) Product Images from "BR55 Ultrasound Molecular Imaging of Clear Cell Renal Cell Carcinoma Reflects Tumor Vascular Expression of VEGFR-2 in a Patient-Derived Xenograft Model"

    Article Title: BR55 Ultrasound Molecular Imaging of Clear Cell Renal Cell Carcinoma Reflects Tumor Vascular Expression of VEGFR-2 in a Patient-Derived Xenograft Model

    Journal: International Journal of Molecular Sciences

    doi: 10.3390/ijms242216211

    ( a ) Correlation (ρ = 0.87, p < 10 −4 ) between AUC and CD34 expression relative to total surface area in IHC and ( b ) Correlation (ρ = 0.72, p < 10 −4 ) between bound MBs signal intensity measured on late-phase BR55 ultrasound and area of VEGFR-2 expression in IHC, relative to tumor surface area. The outer edges of the shaded area represent the confidence bands, indicating the 95% confidence intervals for the mean of the Y-variable at each value of the X-variable. The p -value is indicated with “*” for significant values.
    Figure Legend Snippet: ( a ) Correlation (ρ = 0.87, p < 10 −4 ) between AUC and CD34 expression relative to total surface area in IHC and ( b ) Correlation (ρ = 0.72, p < 10 −4 ) between bound MBs signal intensity measured on late-phase BR55 ultrasound and area of VEGFR-2 expression in IHC, relative to tumor surface area. The outer edges of the shaded area represent the confidence bands, indicating the 95% confidence intervals for the mean of the Y-variable at each value of the X-variable. The p -value is indicated with “*” for significant values.

    Techniques Used: Expressing

    IHC-stained digitized slides of orthotopically PdX-grafted ccRCC tumors. ( a ) Section showing tumor (T) and kidney (K) stained for CD34 ( left ) and VEGFR-2 ( right ), respectively. Bar = 1 mm. ( b ) Zoom images within the tumor; bar = 100 μm.
    Figure Legend Snippet: IHC-stained digitized slides of orthotopically PdX-grafted ccRCC tumors. ( a ) Section showing tumor (T) and kidney (K) stained for CD34 ( left ) and VEGFR-2 ( right ), respectively. Bar = 1 mm. ( b ) Zoom images within the tumor; bar = 100 μm.

    Techniques Used: Staining

    rat anti mouse cd34 antibody  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Hycult Biotech rat anti mouse cd34 antibody
    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, <t>CD34</t> and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.
    Rat Anti Mouse Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34 antibody/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 antibody - by Bioz Stars, 2024-04
    86/100 stars

    Images

    1) Product Images from "DiPRO1 dependent transcriptional and epigenetic regulation distinctly controls the fate of muscle and mesenchymal cancer cells"

    Article Title: DiPRO1 dependent transcriptional and epigenetic regulation distinctly controls the fate of muscle and mesenchymal cancer cells

    Journal: bioRxiv

    doi: 10.1101/2023.01.08.523169

    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, CD34 and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.
    Figure Legend Snippet: Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, CD34 and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.

    Techniques Used: Activity Assay, Quantitative RT-PCR, Expressing, Inhibition, Immunohistochemical staining, Staining, TUNEL Assay

    rat monoclonal anti cd34 antibody  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech rat monoclonal anti cd34 antibody
    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, <t>CD34</t> and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.
    Rat Monoclonal Anti Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat monoclonal anti cd34 antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat monoclonal anti cd34 antibody - by Bioz Stars, 2024-04
    93/100 stars

    Images

    1) Product Images from "DiPRO1 dependent transcriptional and epigenetic regulation distinctly controls the fate of muscle and mesenchymal cancer cells"

    Article Title: DiPRO1 dependent transcriptional and epigenetic regulation distinctly controls the fate of muscle and mesenchymal cancer cells

    Journal: bioRxiv

    doi: 10.1101/2023.01.08.523169

    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, CD34 and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.
    Figure Legend Snippet: Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, CD34 and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.

    Techniques Used: Activity Assay, Quantitative RT-PCR, Expressing, Inhibition, Immunohistochemical staining, Staining, TUNEL Assay

    rat anti mouse cd34 staining  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Hycult Biotech rat anti mouse cd34 staining
    ( A ) Representative pictures of <t>CD34-stained</t> Colo205 tumors (mean 800 mm 3 ). ( B ) Quantitative analysis of tumor microvessel density (MVD). MVD was quantified in <t>CD34-stained</t> whole tumor slides. LC06 and LC08 treatment led to a significant reduction of intratumoral MVD (n = 5, *p<0.05 compared to control, Student's t-test). ( C ) Quantification of vessel coverage calculated as the percentage of desmin-positive vessels in relation to <t>CD34-positive</t> endothelial cells staining in six random regions of 1000×1000 µm per tumor slide. LC06 and LC08 treated tumors showed increased vessel coverage by desmin positive pericytes (n = 5 mice per group, *p<0.05 compared to control, Student's t-test). ( D ) The average vessel area of intratumoral microvessels were significantly reduced in tumors treated with LC06 and LC08 (n = 5, *p<0.05 compared to control, Student's t-test). ( E ) Perfusion was assessed based on analysis of TRITC-lectin perfusion and CD34-positive staining in six random regions of 1000×1000 µm per tumor slide. Almost all remaining intratumoral microvessels were perfused in LC06 (93%) and LC08 (97%) treated tumors compared to control (56%) (n = 5 mice per group, *p<0.01). ( F ) Number of branched intratumoral microvessels was counted in six random regions of 1000×1000 µm per tumor slide and calculated per mm 2 and was significantly reduced in tumors treated with LC06 and LC08. LC06 treatment resulted in stronger inhibition of vessel branching compared to pan-Ang-2/-1 treatment via LC08 (n = 5, *p<0.01 compared to control; # p<0.01 compared to LC08, Student's t-test). Results are expressed as mean ± SEM. Scale bars represent 500 µm.
    Rat Anti Mouse Cd34 Staining, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34 staining/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 staining - by Bioz Stars, 2024-04
    86/100 stars

    Images

    1) Product Images from "A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors"

    Article Title: A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0054923

    ( A ) Representative pictures of CD34-stained Colo205 tumors (mean 800 mm 3 ). ( B ) Quantitative analysis of tumor microvessel density (MVD). MVD was quantified in CD34-stained whole tumor slides. LC06 and LC08 treatment led to a significant reduction of intratumoral MVD (n = 5, *p<0.05 compared to control, Student's t-test). ( C ) Quantification of vessel coverage calculated as the percentage of desmin-positive vessels in relation to CD34-positive endothelial cells staining in six random regions of 1000×1000 µm per tumor slide. LC06 and LC08 treated tumors showed increased vessel coverage by desmin positive pericytes (n = 5 mice per group, *p<0.05 compared to control, Student's t-test). ( D ) The average vessel area of intratumoral microvessels were significantly reduced in tumors treated with LC06 and LC08 (n = 5, *p<0.05 compared to control, Student's t-test). ( E ) Perfusion was assessed based on analysis of TRITC-lectin perfusion and CD34-positive staining in six random regions of 1000×1000 µm per tumor slide. Almost all remaining intratumoral microvessels were perfused in LC06 (93%) and LC08 (97%) treated tumors compared to control (56%) (n = 5 mice per group, *p<0.01). ( F ) Number of branched intratumoral microvessels was counted in six random regions of 1000×1000 µm per tumor slide and calculated per mm 2 and was significantly reduced in tumors treated with LC06 and LC08. LC06 treatment resulted in stronger inhibition of vessel branching compared to pan-Ang-2/-1 treatment via LC08 (n = 5, *p<0.01 compared to control; # p<0.01 compared to LC08, Student's t-test). Results are expressed as mean ± SEM. Scale bars represent 500 µm.
    Figure Legend Snippet: ( A ) Representative pictures of CD34-stained Colo205 tumors (mean 800 mm 3 ). ( B ) Quantitative analysis of tumor microvessel density (MVD). MVD was quantified in CD34-stained whole tumor slides. LC06 and LC08 treatment led to a significant reduction of intratumoral MVD (n = 5, *p<0.05 compared to control, Student's t-test). ( C ) Quantification of vessel coverage calculated as the percentage of desmin-positive vessels in relation to CD34-positive endothelial cells staining in six random regions of 1000×1000 µm per tumor slide. LC06 and LC08 treated tumors showed increased vessel coverage by desmin positive pericytes (n = 5 mice per group, *p<0.05 compared to control, Student's t-test). ( D ) The average vessel area of intratumoral microvessels were significantly reduced in tumors treated with LC06 and LC08 (n = 5, *p<0.05 compared to control, Student's t-test). ( E ) Perfusion was assessed based on analysis of TRITC-lectin perfusion and CD34-positive staining in six random regions of 1000×1000 µm per tumor slide. Almost all remaining intratumoral microvessels were perfused in LC06 (93%) and LC08 (97%) treated tumors compared to control (56%) (n = 5 mice per group, *p<0.01). ( F ) Number of branched intratumoral microvessels was counted in six random regions of 1000×1000 µm per tumor slide and calculated per mm 2 and was significantly reduced in tumors treated with LC06 and LC08. LC06 treatment resulted in stronger inhibition of vessel branching compared to pan-Ang-2/-1 treatment via LC08 (n = 5, *p<0.01 compared to control; # p<0.01 compared to LC08, Student's t-test). Results are expressed as mean ± SEM. Scale bars represent 500 µm.

    Techniques Used: Staining, Inhibition

    rat anti mouse cd34  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Hycult Biotech rat anti mouse cd34
    Angiogenesis in wounds removed 14 days after incision is visualized by immunostaining of endothelial cells with antimouse <t>CD34</t> in wild-type ( A + B ), Mmp13 -deficient ( C + D ), Plau -deficient ( E + F ) and Mmp13;Plau double-deficient ( G + H ) mice. The box insets in ( A , C , E + G ) indicate the magnified views shown in ( B , D , F+H ). In ( F + H ) the arrows mark where the vessels protrude into the epidermal layer of the wounds. The scale bar in ( A ) = 0.2 mm and is representative also for ( C , E + G ). The scale bar in ( B ) = 0.1 mm and is representative also for ( D , F + H ).
    Rat Anti Mouse Cd34, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 - by Bioz Stars, 2024-04
    86/100 stars

    Images

    1) Product Images from "Phenotypic Overlap between MMP-13 and the Plasminogen Activation System during Wound Healing in Mice"

    Article Title: Phenotypic Overlap between MMP-13 and the Plasminogen Activation System during Wound Healing in Mice

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0016954

    Angiogenesis in wounds removed 14 days after incision is visualized by immunostaining of endothelial cells with antimouse CD34 in wild-type ( A + B ), Mmp13 -deficient ( C + D ), Plau -deficient ( E + F ) and Mmp13;Plau double-deficient ( G + H ) mice. The box insets in ( A , C , E + G ) indicate the magnified views shown in ( B , D , F+H ). In ( F + H ) the arrows mark where the vessels protrude into the epidermal layer of the wounds. The scale bar in ( A ) = 0.2 mm and is representative also for ( C , E + G ). The scale bar in ( B ) = 0.1 mm and is representative also for ( D , F + H ).
    Figure Legend Snippet: Angiogenesis in wounds removed 14 days after incision is visualized by immunostaining of endothelial cells with antimouse CD34 in wild-type ( A + B ), Mmp13 -deficient ( C + D ), Plau -deficient ( E + F ) and Mmp13;Plau double-deficient ( G + H ) mice. The box insets in ( A , C , E + G ) indicate the magnified views shown in ( B , D , F+H ). In ( F + H ) the arrows mark where the vessels protrude into the epidermal layer of the wounds. The scale bar in ( A ) = 0.2 mm and is representative also for ( C , E + G ). The scale bar in ( B ) = 0.1 mm and is representative also for ( D , F + H ).

    Techniques Used: Immunostaining

    rat anti mouse primary cd34 antibody  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Hycult Biotech rat anti mouse primary cd34 antibody
    A) a single enhancing tumour (at 25 minutes) with corresponding <t>CD34</t> image (C), B) two visible tumors (pre contrast image) with corresponding CD34 images left (D) and right (E).
    Rat Anti Mouse Primary Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse primary cd34 antibody/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse primary cd34 antibody - by Bioz Stars, 2024-04
    86/100 stars

    Images

    1) Product Images from "Primed Infusion with Delayed Equilibrium of Gd.DTPA for Enhanced Imaging of Small Pulmonary Metastases"

    Article Title: Primed Infusion with Delayed Equilibrium of Gd.DTPA for Enhanced Imaging of Small Pulmonary Metastases

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0054903

    A) a single enhancing tumour (at 25 minutes) with corresponding CD34 image (C), B) two visible tumors (pre contrast image) with corresponding CD34 images left (D) and right (E).
    Figure Legend Snippet: A) a single enhancing tumour (at 25 minutes) with corresponding CD34 image (C), B) two visible tumors (pre contrast image) with corresponding CD34 images left (D) and right (E).

    Techniques Used:

    rat anti mouse cd34  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech rat anti mouse cd34
    Immunohistochemical detection of <t>CD34</t> (a vascular endothelial cell marker) and PDGFR-β (a pericyte marker) in the parabiosis model. Six to twelve ovaries were obtained from three to six wild-type mice in their natural estrous cycles. Immunostaining was evaluated on three to four tissue sections in each ovary in each developmental stage of the follicles. The developmental stages are defined in Materials and Methods. Scale bars; 50 μm.
    Rat Anti Mouse Cd34, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 - by Bioz Stars, 2024-04
    93/100 stars

    Images

    1) Product Images from "Locally existing endothelial cells and pericytes in ovarian stroma, but not bone marrow-derived vascular progenitor cells, play a central role in neovascularization during follicular development in mice"

    Article Title: Locally existing endothelial cells and pericytes in ovarian stroma, but not bone marrow-derived vascular progenitor cells, play a central role in neovascularization during follicular development in mice

    Journal: Journal of Ovarian Research

    doi: 10.1186/1757-2215-7-10

    Immunohistochemical detection of CD34 (a vascular endothelial cell marker) and PDGFR-β (a pericyte marker) in the parabiosis model. Six to twelve ovaries were obtained from three to six wild-type mice in their natural estrous cycles. Immunostaining was evaluated on three to four tissue sections in each ovary in each developmental stage of the follicles. The developmental stages are defined in Materials and Methods. Scale bars; 50 μm.
    Figure Legend Snippet: Immunohistochemical detection of CD34 (a vascular endothelial cell marker) and PDGFR-β (a pericyte marker) in the parabiosis model. Six to twelve ovaries were obtained from three to six wild-type mice in their natural estrous cycles. Immunostaining was evaluated on three to four tissue sections in each ovary in each developmental stage of the follicles. The developmental stages are defined in Materials and Methods. Scale bars; 50 μm.

    Techniques Used: Immunohistochemical staining, Marker, Immunostaining

    Double immunostaining for CD34 (a vascular endothelial cell marker) and GFP (a bone marrow derived-cell marker) in the parabiosis model. Blue shows CD34, and brown shows GFP. Double-positive cells are indicated by arrows. T: theca cell layer, G: granulosa cell layer. Scale bars; 50 μm.
    Figure Legend Snippet: Double immunostaining for CD34 (a vascular endothelial cell marker) and GFP (a bone marrow derived-cell marker) in the parabiosis model. Blue shows CD34, and brown shows GFP. Double-positive cells are indicated by arrows. T: theca cell layer, G: granulosa cell layer. Scale bars; 50 μm.

    Techniques Used: Double Immunostaining, Marker, Derivative Assay

    rat anti mouse cd34  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Hycult Biotech rat anti mouse cd34
    Rat Anti Mouse Cd34, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 - by Bioz Stars, 2024-04
    86/100 stars

    Images

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    Hycult Biotech rat anti mouse cd34 antibody
    Rat Anti Mouse Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34 antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 antibody - by Bioz Stars, 2024-04
    93/100 stars
      Buy from Supplier

    93
    Hycult Biotech rat monoclonal anti cd34 antibody
    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, <t>CD34</t> and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.
    Rat Monoclonal Anti Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat monoclonal anti cd34 antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat monoclonal anti cd34 antibody - by Bioz Stars, 2024-04
    93/100 stars
      Buy from Supplier

    86
    Hycult Biotech rat anti mouse cd34 staining
    ( A ) Representative pictures of <t>CD34-stained</t> Colo205 tumors (mean 800 mm 3 ). ( B ) Quantitative analysis of tumor microvessel density (MVD). MVD was quantified in <t>CD34-stained</t> whole tumor slides. LC06 and LC08 treatment led to a significant reduction of intratumoral MVD (n = 5, *p<0.05 compared to control, Student's t-test). ( C ) Quantification of vessel coverage calculated as the percentage of desmin-positive vessels in relation to <t>CD34-positive</t> endothelial cells staining in six random regions of 1000×1000 µm per tumor slide. LC06 and LC08 treated tumors showed increased vessel coverage by desmin positive pericytes (n = 5 mice per group, *p<0.05 compared to control, Student's t-test). ( D ) The average vessel area of intratumoral microvessels were significantly reduced in tumors treated with LC06 and LC08 (n = 5, *p<0.05 compared to control, Student's t-test). ( E ) Perfusion was assessed based on analysis of TRITC-lectin perfusion and CD34-positive staining in six random regions of 1000×1000 µm per tumor slide. Almost all remaining intratumoral microvessels were perfused in LC06 (93%) and LC08 (97%) treated tumors compared to control (56%) (n = 5 mice per group, *p<0.01). ( F ) Number of branched intratumoral microvessels was counted in six random regions of 1000×1000 µm per tumor slide and calculated per mm 2 and was significantly reduced in tumors treated with LC06 and LC08. LC06 treatment resulted in stronger inhibition of vessel branching compared to pan-Ang-2/-1 treatment via LC08 (n = 5, *p<0.01 compared to control; # p<0.01 compared to LC08, Student's t-test). Results are expressed as mean ± SEM. Scale bars represent 500 µm.
    Rat Anti Mouse Cd34 Staining, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34 staining/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 staining - by Bioz Stars, 2024-04
    86/100 stars
      Buy from Supplier

    86
    Hycult Biotech rat anti mouse cd34
    Angiogenesis in wounds removed 14 days after incision is visualized by immunostaining of endothelial cells with antimouse <t>CD34</t> in wild-type ( A + B ), Mmp13 -deficient ( C + D ), Plau -deficient ( E + F ) and Mmp13;Plau double-deficient ( G + H ) mice. The box insets in ( A , C , E + G ) indicate the magnified views shown in ( B , D , F+H ). In ( F + H ) the arrows mark where the vessels protrude into the epidermal layer of the wounds. The scale bar in ( A ) = 0.2 mm and is representative also for ( C , E + G ). The scale bar in ( B ) = 0.1 mm and is representative also for ( D , F + H ).
    Rat Anti Mouse Cd34, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 - by Bioz Stars, 2024-04
    86/100 stars
      Buy from Supplier

    86
    Hycult Biotech rat anti mouse primary cd34 antibody
    A) a single enhancing tumour (at 25 minutes) with corresponding <t>CD34</t> image (C), B) two visible tumors (pre contrast image) with corresponding CD34 images left (D) and right (E).
    Rat Anti Mouse Primary Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse primary cd34 antibody/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse primary cd34 antibody - by Bioz Stars, 2024-04
    86/100 stars
      Buy from Supplier

    Image Search Results


    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, CD34 and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.

    Journal: bioRxiv

    Article Title: DiPRO1 dependent transcriptional and epigenetic regulation distinctly controls the fate of muscle and mesenchymal cancer cells

    doi: 10.1101/2023.01.08.523169

    Figure Lengend Snippet: Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, CD34 and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.

    Article Snippet: Polyclonal rabbit anti-MCM6 (Proteintech, 13347-2-AP) and polyclonal rabbit anti-TIF1B/KAP1 (Merck Millipore, Sigma-Aldrich, ABE1859), mouse monoclonal anti-ICBP90/UHRF1 (Sigma-Aldrich, MABE308), rat monoclonal anti-HA-Peroxidase high affinity (Roche, Sigma-Aldrich, 12013819001), rabbit polyclonal anti-Actin (Sigma-Aldrich, A2103), mouse monoclonal anti-FLAG® M2-Peroxidase (Sigma-Aldrich, A8592), mouse monoclonal anti-Tropomyosin Ab (Sigma-Aldrich, T2780), goat polyclonal anti-rabbit IgG–Peroxidase antibody (Sigma-Aldrich, A6154), Alexa Fluor® 488 Goat Anti-Mouse IgG antibody (Molecular Probes, Invitrogen, A-11001, A11029), Alexa Fluor® 594 Goat Anti-Rabbit IgG antibody (Molecular Probes, Invitrogen, A-11012), Fluoroshield™ with DAPI (Sigma-Aldrich, F6057), Dynabeads™ CD25 (Invitrogen, Thermo Ficher Scientific, 11157D), rat monoclonal anti-CD34 antibody (HycultBiotech, HM1015), Polink-2 Plus HRP Rat-NM Bulk kit for DAB (GBI Labs, D46-110), rabbit monoclonal anti-Ki67 (Neomarkers; LabVision, Thermo Fisher Scientific, RM-9106), rabbit polyclonal cleaved Caspase-3 (Asp175) (Cell Signaling, 9661), anti-FLAG M2 affinity gel (Sigma-Aldrich, A 2220), FLAG® Peptide (Sigma-Aldrich, F3290), Protein A agarose (Pierce, Thermo Ficher Scientific, 20333).

    Techniques: Activity Assay, Quantitative RT-PCR, Expressing, Inhibition, Immunohistochemical staining, Staining, TUNEL Assay

    ( A ) Representative pictures of CD34-stained Colo205 tumors (mean 800 mm 3 ). ( B ) Quantitative analysis of tumor microvessel density (MVD). MVD was quantified in CD34-stained whole tumor slides. LC06 and LC08 treatment led to a significant reduction of intratumoral MVD (n = 5, *p<0.05 compared to control, Student's t-test). ( C ) Quantification of vessel coverage calculated as the percentage of desmin-positive vessels in relation to CD34-positive endothelial cells staining in six random regions of 1000×1000 µm per tumor slide. LC06 and LC08 treated tumors showed increased vessel coverage by desmin positive pericytes (n = 5 mice per group, *p<0.05 compared to control, Student's t-test). ( D ) The average vessel area of intratumoral microvessels were significantly reduced in tumors treated with LC06 and LC08 (n = 5, *p<0.05 compared to control, Student's t-test). ( E ) Perfusion was assessed based on analysis of TRITC-lectin perfusion and CD34-positive staining in six random regions of 1000×1000 µm per tumor slide. Almost all remaining intratumoral microvessels were perfused in LC06 (93%) and LC08 (97%) treated tumors compared to control (56%) (n = 5 mice per group, *p<0.01). ( F ) Number of branched intratumoral microvessels was counted in six random regions of 1000×1000 µm per tumor slide and calculated per mm 2 and was significantly reduced in tumors treated with LC06 and LC08. LC06 treatment resulted in stronger inhibition of vessel branching compared to pan-Ang-2/-1 treatment via LC08 (n = 5, *p<0.01 compared to control; # p<0.01 compared to LC08, Student's t-test). Results are expressed as mean ± SEM. Scale bars represent 500 µm.

    Journal: PLoS ONE

    Article Title: A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors

    doi: 10.1371/journal.pone.0054923

    Figure Lengend Snippet: ( A ) Representative pictures of CD34-stained Colo205 tumors (mean 800 mm 3 ). ( B ) Quantitative analysis of tumor microvessel density (MVD). MVD was quantified in CD34-stained whole tumor slides. LC06 and LC08 treatment led to a significant reduction of intratumoral MVD (n = 5, *p<0.05 compared to control, Student's t-test). ( C ) Quantification of vessel coverage calculated as the percentage of desmin-positive vessels in relation to CD34-positive endothelial cells staining in six random regions of 1000×1000 µm per tumor slide. LC06 and LC08 treated tumors showed increased vessel coverage by desmin positive pericytes (n = 5 mice per group, *p<0.05 compared to control, Student's t-test). ( D ) The average vessel area of intratumoral microvessels were significantly reduced in tumors treated with LC06 and LC08 (n = 5, *p<0.05 compared to control, Student's t-test). ( E ) Perfusion was assessed based on analysis of TRITC-lectin perfusion and CD34-positive staining in six random regions of 1000×1000 µm per tumor slide. Almost all remaining intratumoral microvessels were perfused in LC06 (93%) and LC08 (97%) treated tumors compared to control (56%) (n = 5 mice per group, *p<0.01). ( F ) Number of branched intratumoral microvessels was counted in six random regions of 1000×1000 µm per tumor slide and calculated per mm 2 and was significantly reduced in tumors treated with LC06 and LC08. LC06 treatment resulted in stronger inhibition of vessel branching compared to pan-Ang-2/-1 treatment via LC08 (n = 5, *p<0.01 compared to control; # p<0.01 compared to LC08, Student's t-test). Results are expressed as mean ± SEM. Scale bars represent 500 µm.

    Article Snippet: The tumor vasculature was detected in 2-μm paraffin sections by rat anti-mouse CD34 staining (Hycult Biotechnology, Uden, Netherlands) and a biotinylated rabbit anti rat IgG (Vector Labs, Burlingame, CA, USA) or in 10-µm cryosections by rat anti-mouse CD31 staining (BD Pharmingen, San Diego, CA, USA) and a goat anti-rat IgG conjugated with Alexa 546 (Invitrogen, Carlsbad, CA, USA).

    Techniques: Staining, Inhibition

    Angiogenesis in wounds removed 14 days after incision is visualized by immunostaining of endothelial cells with antimouse CD34 in wild-type ( A + B ), Mmp13 -deficient ( C + D ), Plau -deficient ( E + F ) and Mmp13;Plau double-deficient ( G + H ) mice. The box insets in ( A , C , E + G ) indicate the magnified views shown in ( B , D , F+H ). In ( F + H ) the arrows mark where the vessels protrude into the epidermal layer of the wounds. The scale bar in ( A ) = 0.2 mm and is representative also for ( C , E + G ). The scale bar in ( B ) = 0.1 mm and is representative also for ( D , F + H ).

    Journal: PLoS ONE

    Article Title: Phenotypic Overlap between MMP-13 and the Plasminogen Activation System during Wound Healing in Mice

    doi: 10.1371/journal.pone.0016954

    Figure Lengend Snippet: Angiogenesis in wounds removed 14 days after incision is visualized by immunostaining of endothelial cells with antimouse CD34 in wild-type ( A + B ), Mmp13 -deficient ( C + D ), Plau -deficient ( E + F ) and Mmp13;Plau double-deficient ( G + H ) mice. The box insets in ( A , C , E + G ) indicate the magnified views shown in ( B , D , F+H ). In ( F + H ) the arrows mark where the vessels protrude into the epidermal layer of the wounds. The scale bar in ( A ) = 0.2 mm and is representative also for ( C , E + G ). The scale bar in ( B ) = 0.1 mm and is representative also for ( D , F + H ).

    Article Snippet: Tissue sections were stained with the following antibodies: rabbit anti-mouse keratin 10 (1∶2000, BabCO, Richmond, CA, USA), rabbit anti-mouse keratin 14 (1∶2000, Covance, Berkeley, CA, USA), rat anti-mouse CD34 (1∶100, HyCult Biotechnology, Uden, The Netherlands) and rat anti-mouse F4/80 (BM8) (1∶200, eBioscience, San Diego, CA, USA).

    Techniques: Immunostaining

    A) a single enhancing tumour (at 25 minutes) with corresponding CD34 image (C), B) two visible tumors (pre contrast image) with corresponding CD34 images left (D) and right (E).

    Journal: PLoS ONE

    Article Title: Primed Infusion with Delayed Equilibrium of Gd.DTPA for Enhanced Imaging of Small Pulmonary Metastases

    doi: 10.1371/journal.pone.0054903

    Figure Lengend Snippet: A) a single enhancing tumour (at 25 minutes) with corresponding CD34 image (C), B) two visible tumors (pre contrast image) with corresponding CD34 images left (D) and right (E).

    Article Snippet: Antibodies for CD34 detection were as follows; rat anti-mouse primary CD34 antibody at a 1∶5 dilution (Hycult Biotech, The Netherlands), biotinylated secondary antibody at a 1∶200 dilution (Dako, Denmark).

    Techniques: